Su E J, Fredriksson L, Schielke G P, Eriksson U, Lawrence D A
Department of Internal Medicine, University of Michigan Medical School, MI 48109, USA.
J Thromb Haemost. 2009 Jul;7 Suppl 1(Suppl 1):155-8. doi: 10.1111/j.1538-7836.2009.03402.x.
The use of tissue plasminogen activator (tPA) as a thrombolytic treatment in ischemic stroke is limited largely due to concerns for hemorrhagic complications. The underlying mechanisms are still unknown, but evidence is beginning to emerge that tPA interacts with key regulators of the neurovascular unit (NVU), and that these interactions may contribute to the undesirable side effects associated with the use of tPA in ischemic stroke. Understanding these connections and tPA's normal function within the NVU may offer new insights into future therapeutic approaches.
组织型纤溶酶原激活剂（tPA）在缺血性卒中中作为溶栓治疗的应用受到很大限制，主要是因为担心出血并发症。其潜在机制尚不清楚，但已有证据表明，tPA与神经血管单元（NVU）的关键调节因子相互作用，而这些相互作用可能导致tPA在缺血性卒中应用中出现不良副作用。了解这些联系以及tPA在NVU中的正常功能，可能为未来的治疗方法提供新的见解。
